GSK Earnings Date: Feb 3, 2027 (Estimated) — GSK plc
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is GSK's next earnings date?
GSK plc (GSK) is expected to report Q4 2026 earnings on Wednesday, February 3, 2027 at 2:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.76 on revenue of $12.13B.
How did GSK do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), GSK plc posted EPS of $1.47 versus the $1.33 estimate, a beat of 10.5%. Revenue was $11.83B against a $11.78B estimate. The stock's 1-day post-earnings move was -4.3%.
How much does GSK stock move after earnings?
GSK beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
🤖 AI Earnings Analysis
Specialty-medicine demand powered a solid Q3 beat, offsetting weaker vaccines and flat general medicines; EPS of $1.47 topped estimates by $0.14. GSK maintained annual targets, while oncology pipeline expansion adds longer-term upside.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 1.33 | 1.47 | +10.53% | $11.83B | ✅ Beat | -4.32% | — | — |
| 2026-07-28 | Q2 2026 | 1.27 | 1.35 | +6.61% | $11.28B | ✅ Beat | +3.34% | -0.89% | +1.07% |
| 2026-04-29 | Q1 2026 | 1.17 | 1.25 | +6.84% | $10.30B | ✅ Beat | -5.64% | -7.51% | -5.10% |
| 2026-02-04 | Q4 2025 | 0.64 | 0.68 | +6.25% | $11.46B | ✅ Beat | +7.29% | +10.27% | +4.42% |
| 2025-10-29 | Q3 2025 | 1.26 | 1.48 | +17.78% | $11.53B | ✅ Beat | +5.09% | +7.13% | +10.85% |
| 2025-07-30 | Q2 2025 | 1.12 | 1.24 | — | $10.66B | ✅ Beat | +3.44% | -0.94% | +7.08% |
| 2025-04-30 | Q1 2025 | 1.04 | 1.13 | +8.65% | $9.46B | ✅ Beat | +2.25% | -3.77% | +3.83% |
| 2025-02-05 | Q4 2024 | 0.43 | 0.58 | +34.88% | $10.06B | ✅ Beat | +8.20% | +3.53% | +14.03% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2025 · $15.13B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| International | 54.7% | $8.28B | — | — | — | — | — |
| Europe | 45.3% | $6.85B | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.